8 дек. 2020 г. · This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), ...

This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), ...

This review discusses key genes involved in the pathogenesis and pathophysiology of AD, as well as the disease's molecular mechanisms.

22 окт. 2024 г. · This paper will discuss the genetic causes of AD, the process behind the formation of neurofibrillary tangles and amyloid plaques, recent neuroimaging ...

This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), ...

AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk ...

The identification of biomarkers of aging would provide a powerful tool for monitoring the effects of aging and for developing interventions to improve ...

16 сент. 2024 г. · This paper will discuss the genetic causes of AD, the process behind the formation of neurofibrillary tangles and amyloid plaques, recent neuroimaging ...

Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a ...

Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to -methyl d-aspartate (NMDA) ...